Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations
Open Access
- 1 April 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4) , 2129-2135
Abstract
The Mycobacterium avium complex is the most common cause of nontuberculous mycobacterial lung disease worldwide; yet, an optimal treatment regimen for M. avium complex infection has not been established. Clarithromycin is accepted as the cornerstone drug for treatment of M. avium lung disease; however, good model systems, especially animal models, are needed to evaluate the most effective companion drugs. We performed a series of experiments to evaluate and use different mouse models (comparing BALB/c, C57BL/6, nude, and beige mice) of M. avium infection and to assess the anti- M. avium activity of single and combination drug regimens, in vitro , ex vivo , and in mice. In vitro , clarithromycin and moxifloxacin were most active against M. avium , and no antagonism was observed between these two drugs. Nude mice were more susceptible to M. avium infection than the other mouse strains tested, but the impact of treatment was most clearly seen in M. avium -infected BALB/c mice. The combination of clarithromycin-ethambutol-rifampin was more effective in all infected mice than moxifloxacin-ethambutol-rifampin; the addition of moxifloxacin to the clarithromycin-containing regimen did not increase treatment efficacy. Clarithromycin-containing regimens are the most effective for M. avium infection; substitution of moxifloxacin for clarithromycin had a negative impact on treatment efficacy.Keywords
This publication has 36 references indexed in Scilit:
- Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010Emerging Infectious Diseases, 2013
- Staphylococcal Infections in Children, California, USA, 1985–2009Emerging Infectious Diseases, 2013
- Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare BeneficiariesAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic LesionsThe Journal of Infectious Diseases, 2011
- Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient MiceAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Isoniazid or Moxifloxacin in Rifapentine-based Regimens for Experimental Tuberculosis?American Journal of Respiratory and Critical Care Medicine, 2008
- Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine ModelPLOS Medicine, 2007
- In Vitro and In Vivo Activities of Novel Fluoroquinolones Alone and in Combination with Clarithromycin against Clinically Isolated Mycobacterium avium Complex Strains in JapanAntimicrobial Agents and Chemotherapy, 2007
- Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone AntibacterialClinical Pharmacokinetics, 2003